|
Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs. Syncona, a London-based investor in healthcare companies, noted that Autolus reported a pretax loss of $52.7 million for the first quarter of 2024, widening from $39.8 million a year prior. Notably, license revenue surged to $10.1 million from $1.3 million. However, general and administrative costs nearly doubled to $18.2 million from $9.3 million, while operating expenses classified as ‘other’ increased to $13.9 million from $677,000. Autolus expects initial clinical data from a phase 1 dose confirmation study in refractory systemic lupus erythematosus patients in late 2024. Syncona holds a stake of around 14% in Autolus. Syncona shares fell 2.9% to 107.00 pence each on Friday afternoon in London. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
